Get MindMed Updates:
with Psychedelic Inspired Medicines
zero to negligible hallucination effect
in accordance with diagnosis, for the purpose of healing
at-home use with daily or weekly administration
21 million Americans have at least one addiction, yet despite focused efforts in the space, which are saving lives on a daily basis, only 10% of those individuals receive treatment4. Addiction is a brain disease, driven by a set of disease processes including the dysregulation of dopamine, a potent neurotransmitter, in the brain’s reward/pleasure center located in the midbrain.
We are developing 18-MC to treat the cause of the brain disease that is addiction, rather than solely the symptoms. Sustained mental healing requires addressing a root cause and a comprehensive approach for the entire patient journey.
Cue-induced reinstatement, or relapse, is when an individual with a substance use disorder is prompted by their surroundings to consume a harmful substance (example: The clink of a wine glass at a dinner party for a person with an alcohol use disorder).
Our intent is to develop and deploy a treatment that can solve for one of the most common and challenging aspects of substance use disorders, cue-induced relapse
Dr. Stanley Glick (Scientific Advisor) invented 18-MC as a solution for addiction.
Ibogaine is a Schedule 1 substance extracted from the West Africa iboga shrub with anti-addictive properties but has potential to induce heart attacks
Our scientists and chemists have invented a better version of ibogaine, a derivative called 18-MC
Designed to correct the dysregulation in the brain’s reward/pleasure center to treat addiction without the hallucinogenic and potential negative side effects of ibogaine
MindMed’s approach to addiction is predicated on the understanding that while there have been substantial strides in treating some substance use disorders, more tools are desperately needed to help people in need. We recognize that there remain multiple use disorders without any currently approved treatments.”
Adult suffering in US from ADHD5
Adults with ADHD who are receiving treatment6
Between 2007 and 2016 alone, the rate amongst adults increased by 123%. 7
Microdosing refers to a smaller, non-hallucinogenic dose of LSD. In these cases, the medicinal properties of the compound address the illness and may not require a hallucinogenic dose as a component of healing.
Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:
Rigorous scientific trials are in progress to validate these claims and ensure the highest standards of quality, safety, and efficacy for medical use if approved. This is where MindMed’s Microdosing Division comes in.